2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
118
Neoplasms
110
Lung Neoplasms
65
Colorectal Neoplasms
52
Prostatic Neoplasms
46
Carcinoma, Non-Small-Cell Lung
46
Pancreatic Neoplasms
34
Melanoma
33
Ovarian Neoplasms
29
Neoplastic Cells, Circulating
29
Head and Neck Neoplasms
27
Uterine Cervical Neoplasms
23
Multiple Myeloma
20
Glioma
20
Colonic Neoplasms
20
Carcinoma, Hepatocellular
20
Sarcoma
19
Leukemia, Myeloid, Acute
18
Neoplasm Metastasis
17
Lymphoma
15
Glioblastoma
15
Esophageal Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Hematologic Neoplasms
14
Endometrial Neoplasms
14
Leukemia
13
Myelodysplastic Syndromes
11
Kidney Neoplasms
11
Gastrointestinal Neoplasms
11
Carcinoma, Renal Cell
11
Interventions
Insulin Glargine
4
Insulin
3
Alpelisib
3
volagidemab
2
Metformin
2
Fulvestrant
2
ziprasidone
1
relacorilant
1
pembrolizumab
1
olaparib
1
exemestane
1
dapagliflozin
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
Electrocardiography
1
DNA, Ribosomal
1
Control Groups
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hyperglycemia
×
Blood Specimen Collection
×
Clear all
NCT03978702
2022-01-06
IMMUNOPANC
Institut Paoli-Calmettes
Phase NA
Unknown
40 enrolled